- Home
- / Pharmacyclics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pharmacyclics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$729.7 M
FY, 2014
CreditSafe Score
?
Score changed on Dec 13, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 |
|---|---|---|---|
| Revenue | 160.7M | 260.2M | 729.7M |
| Revenue growth, % | 180.5% | ||
| Cost of goods sold | 3.5M | 40.4M | |
| Gross profit | 256.7M | 689.3M | |
| Gross profit margin, % | 98.7% | 94.5% | |
| General and administrative expense | 11.3M | 104.0M | 168.0M |
| Operating expense total | 40.6M | 158.7M | 566.9M |
| Depreciation and amortization | 520.0K | ||
| EBIT | 120.1M | 97.9M | 122.4M |
| EBIT margin, % | 74.7% | 37.6% | 16.8% |
| Interest income | 137.0K | 341.0K | 440.0K |
| Pre tax profit | 120.2M | 98.1M | 122.4M |
| Income tax expense | 2.6M | 31.1M | 36.3M |
| Net Income | 117.5M | 67.0M | 86.1M |